Concepedia

David Fandrei

DF

Statistics

Publications

6

Citations

170

H-Index

6

Active since

2024

Affiliations

University Hospital Leipzig(Current)

Universität Hamburg

University Medical Center Hamburg-Eppendorf

Heinrich Heine University Düsseldorf

Fraunhofer Institute for Cell Therapy and Immunology

David Fandrei is an author at University Hospital Leipzig specializing in oncology, multiple myeloma treatment, and refractory multiple myeloma.

ORCID

Publications per year

2024–2025

6

Publications

6

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

David Fandrei, Sabine Seiffert, Michael Rade et al. · Blood Cancer Discovery · 2024 · 42 citations · Full text

, , +15

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study

Maximilian Merz, Anca‐Maria Albici, Bastian von Tresckow et al. · HemaSphere · 2025 · 38 citations · Full text

, , +13

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody

Till Braun, Michael Rade, Maximilian Merz et al. · Nature Medicine · 2025 · 32 citations

, , +17

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Binod Dhakal, Othman Salim Akhtar, David Fandrei et al. · Blood · 2025 · 24 citations

, , +17

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Maximilian Merz, Danai Dima, Hamza Hashmi et al. · Blood Cancer Journal · 2024 · 22 citations · Full text

, , +17

1–5 of 6